Target Group Inc banner

Target Group Inc
OTC:CBDY

Watchlist Manager
Target Group Inc Logo
Target Group Inc
OTC:CBDY
Watchlist
Price: 0.0016 USD Market Closed
Market Cap: $987.2k

EV/S

0.2
Current
7%
More Expensive
vs 3-y average of 0.2

Enterprise Value to Sales (EV/S) ratio compares a company`s total enterprise value to its revenue. It shows how much investors are paying for each dollar of the company`s sales, including both equity and debt.

EV/S
0.2
=
Enterprise Value
$1m
/
Revenue
$3.9m

Enterprise Value to Sales (EV/S) ratio compares a company`s total enterprise value to its revenue. It shows how much investors are paying for each dollar of the company`s sales, including both equity and debt.

EV/S
0.2
=
Enterprise Value
$1m
/
Revenue
$3.9m

Valuation Scenarios

Target Group Inc is trading above its 3-year average

If EV/S returns to its 3-Year Average (0.2), the stock would be worth $0 (7% downside from current price).

Statistics
Positive Scenarios
2/4
Maximum Downside
-7%
Maximum Upside
+1 177%
Average Upside
425%
Scenario EV/S Value Implied Price Upside/Downside
Current Multiple 0.2 $0
0%
3-Year Average 0.2 $0
-7%
5-Year Average 0.2 $0
-7%
Industry Average 1.5 $0.01
+537%
Country Average 2.9 $0.02
+1 177%

Forward EV/S
Today’s price vs future revenue

Not enough data available to calculate forward EV/S

Peer Comparison

All Multiples
EV/S
P/E
All Countries
Close
Market Cap EV/S P/E
CA
Target Group Inc
OTC:CBDY
987.2k USD 0.2 -0.7
US
Eli Lilly and Co
NYSE:LLY
835.2B USD 13.3 40.5
US
Johnson & Johnson
NYSE:JNJ
547.8B USD 6 26
CH
Roche Holding AG
SIX:ROG
248.4B CHF 4.7 20.1
UK
AstraZeneca PLC
LSE:AZN
216.4B GBP 5.2 28
CH
Novartis AG
SIX:NOVN
223.1B CHF 5.2 19.6
US
Merck & Co Inc
NYSE:MRK
276.9B USD 4.8 15.2
IE
Endo International PLC
LSE:0Y5F
244.4B USD 108.7 -83.6
DK
Novo Nordisk A/S
CSE:NOVO B
1.1T DKK 4 11.3
US
Pfizer Inc
NYSE:PFE
153.5B USD 3.2 19.8
US
Bristol-Myers Squibb Co
NYSE:BMY
118.2B USD 3.1 16.8
P/E Multiple
Earnings Growth PEG
CA
Target Group Inc
OTC:CBDY
Average P/E: 21.9
Negative Multiple: -0.7
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
40.5
32%
1.3
US
Johnson & Johnson
NYSE:JNJ
26
8%
3.3
CH
Roche Holding AG
SIX:ROG
20.1
14%
1.4
UK
AstraZeneca PLC
LSE:AZN
28
25%
1.1
CH
Novartis AG
SIX:NOVN
19.6
14%
1.4
US
Merck & Co Inc
NYSE:MRK
15.2
14%
1.1
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -83.6 N/A N/A
DK
Novo Nordisk A/S
CSE:NOVO B
11.3
0%
N/A
US
Pfizer Inc
NYSE:PFE
19.8
22%
0.9
US
Bristol-Myers Squibb Co
NYSE:BMY
16.8
16%
1

Market Distribution

Lower than 99% of companies in Canada
Percentile
1st
Based on 2 384 companies
1st percentile
0.2
Low
0 — 1.7
Typical Range
1.7 — 5.7
High
5.7 —
Distribution Statistics
Canada
Min 0
30th Percentile 1.7
Median 2.9
70th Percentile 5.7
Max 15 639 353.3

Target Group Inc
Glance View

Market Cap
987.2k USD
Industry
Pharmaceuticals

Target Group, Inc. (Canada) is an investment holding company. The company is headquartered in Vaughan, Ontario and currently employs 45 full-time employees. The company went IPO on 2015-09-22. The firm is engaged in the cultivation, processing and distribution of curated cannabis products for the adult-use medical and recreational cannabis market in Canada and in the United States. Its products include cannabis flower pods and cannabis extract pods for vaporizer use, cannabis pre-rolls, K-Cup infused coffee and tea pods, infused cannabis beverages, infused cannabis edibles and infused topical products and cannabinoid (CBD) wellness products. The firm's subsidiary, Canary Rx Inc, is a Canadian licensed producer, which operates an approximately 44,000 square foot facility located in Norfolk County, Ontario. Its subsidiary, CannaKorp Inc., has developed a single-use pre-measured pod and vaporizer system, such as The Wisp and Wisp Pods for consumers interested in vaporizing natural herbs, including cannabis.

CBDY Intrinsic Value
0.0108 USD
Undervaluation 85%
Intrinsic Value
Price $0.0016
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett